A dose-escalation study of aerosolized sargramostim in the treatment of metastatic melanoma: An NCCTG study

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 6, 2008, Pages 573-579

  Markovic, Svetomir N ^a   Suman, Vera J ^a   Nevala, Wendy K ^a   Geeraerts, Louis ^b   Creagan, Edward T ^a   Erickson, Lori A ^a   Rowland Jr , Kendrith M ^c   Morton, Roscoe F ^d   Horvath, William L ^e   Pittelkow, Mark R ^a  

^a MAYO CLINIC   (United States)

^b MeritCare Hospital   (United States)

^c Carle Cancer Center CCOP   (United States)

^d Oncology Research Association CCOP   (United States)

^e Hematology Oncology Associates of Ohio and Michigan   (United States)

Author keywords

Aerosol; Granulocyte macrophage colony stimulating factor; Immunotherapy; Melanoma

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; HUMAN; IMMUNE RESPONSE; LUNG FUNCTION; MALE; MELANOMA; NAUSEA;

ADMINISTRATION, INHALATION; ADULT; AEROSOLS; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTORS, RECOMBINANT; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME;

EID: 58149230993     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318173a536     Document Type: Article

References (23)

1. Dranoff G. GM-CSF-based cancer vaccines. Immunol Rev. 2002;188: 147-154.
2. Dranoff G. GM-CSF-secreting melanoma vaccines. Oncogene. 2003;22: 3188-3192.
3. Ridolfi L, Ridolfi R, Ascari-Raccagni A, et al. Intralesional granulocyte-monocyte colony-stimulating factor followed by subcutaneous interleukin-2 in metastatic melanoma: a pilot study in elderly patients. J Eur Acad Dermatol Venereol. 2001;15:218-223.
4. Ridolfi L, Ridolfi R. Preliminary experiences of intralesional immunotherapy in cutaneous metastatic melanoma. Hepatogastroenterology. 2002;49:335-339.
5. Hoeller C, Jansen B, Heere-Ress E, et al. Perilesional injection of r-GM-CSF in patients with cutaneous melanoma metastases. J Invest Dermatol. 2001;117:371-374.
6. Rao RD, Anderson PM, Arndt CA, et al. Aerosolized granulocyte macrophage colony-stimulating factor (GM-CSF) therapy in metastatic cancer. Am J Clin Oncol. 2003;26:493-498.
7. Rao RD, Markovic SN, Anderson PM. Aerosol therapy for malignancy involving the lungs. Curr Cancer Drug Targets. 2003;3:239-250.
8. Anderson PM, Markovic SN, Sloan JA, et al. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res. 1999;5:2316-2323.
9. Tazawa R, Hamano E, Arai T, et al. Granulocyte-macrophage colony-stimulating factor and lung immunity in pulmonary alveolar proteinosis. Am J Respir Crit Care Med. 2005;171:1142-1149.
10. Markovic SN, Suman VJ, Ingle JN, et al. Peptide vaccination of patients with metastatic melanoma: improved clinical outcome in patients demonstrating effective immunization. Am J Clin Oncol. 2006;29:352-360.
11. Sabin AB. Immunization against measles by aerosol. Rev Infect Dis. 1983;5:514-523.
12. Sabin AB, Albrecht P, Takeda AK, et al. High effectiveness of aerosolized chick embryo fibroblast measles vaccine in seven-month-old and older infants. J Infect Dis. 1985;152:1231-1237.
13. Sabin AB, Fernandez de Castro J, Flores Arechiga A, et al. Clinical trials of inhaled aerosol of human diploid and chick embryo measles vaccine. Lancet. 1982;2:604.
14. Sabin AB, Flores Arechiga A, Fernandez de Castro J, et al. Successful immunization of infants with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA. 1984;251:2363-2371.
15. Sabin AB, Flores Arechiga A, Fernandez de Castro J, et al. Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines. JAMA. 1983;249: 2651-2662.
16. Stephenson I, Zambon MC, Rudin A, et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol. 2006;80:4962-4970.
17. Oh Y, Ohta K, Kuno-Sakai H, et al. Local and systemic influenza haemagglutinin-specific antibody responses following aerosol and subcutaneous administration of inactivated split influenza vaccine. Vaccine. 1992;10:506-511.
18. O'Hagan DT. Recent advances in vaccine adjuvants for systemic and mucosal administration. J Pharm Pharmacol. 1998;50:1-10.
19. Muszkat M, Yehuda AB, Schein MH, et al. Local and systemic immune response in community-dwelling elderly after intranasal or intramuscular immunization with inactivated influenza vaccine. J Med Virol. 2000;61:100-106.
20. McCarthy MW, Kockler DR. Trivalent intranasal influenza vaccine, live. Ann Pharmacother. 2004;38:2086-2093.
21. Kuno-Sakai H, Kimura M, Ohta K, et al. Developments in mucosal influenza virus vaccines. Vaccine. 1994;12:1303-1310.
22. Denis F, Alain S, Ploy MC. New routes of administration: epidermal, transcutaneous mucosal ways of vaccination. Med Sci (Paris). 2007;23: 379-385.
23. Boyce TG, Hsu HH, Sannella EC, et al. Safety and immunogenicity of adjuvanted and unadjuvanted subunit influenza vaccines administered intranasally to healthy adults. Vaccine. 2000;19:217-226.